Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

DURECT

Nasdaq:DRRX
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DRRX
Nasdaq
$305M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • DURECT has significant price volatility in the past 3 months.
DRRX Share Price and Events
7 Day Returns
22.8%
NasdaqCM:DRRX
5.2%
US Pharmaceuticals
9.9%
US Market
1 Year Returns
155.3%
NasdaqCM:DRRX
-12.4%
US Pharmaceuticals
-11.9%
US Market
DRRX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
DURECT (DRRX) 22.8% -11.9% -58.9% 155.3% 52.9% -14.3%
US Pharmaceuticals 5.2% -8.4% -16.6% -12.4% -0.9% -1.7%
US Market 9.9% -15% -21.5% -11.9% 5.1% 18.1%
1 Year Return vs Industry and Market
  • DRRX outperformed the Pharmaceuticals industry which returned -12.4% over the past year.
  • DRRX outperformed the Market in United States of America which returned -11.9% over the past year.
Price Volatility
DRRX
Industry
5yr Volatility vs Market

DRRX Value

 Is DURECT undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for DURECT. This is due to cash flow or dividend data being unavailable. The share price is $1.56.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for DURECT's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are DURECT's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:DRRX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.12
NasdaqCM:DRRX Share Price ** NasdaqCM (2020-03-27) in USD $1.56
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.11x
United States of America Market PE Ratio Median Figure of 2,945 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of DURECT.

NasdaqCM:DRRX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:DRRX Share Price ÷ EPS (both in USD)

= 1.56 ÷ -0.12

-13.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DURECT is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • DURECT is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does DURECT's expected growth come at a high price?
Raw Data
NasdaqCM:DRRX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-4.1%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.83x
United States of America Market PEG Ratio Median Figure of 2,007 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for DURECT, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on DURECT's assets?
Raw Data
NasdaqCM:DRRX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.12
NasdaqCM:DRRX Share Price * NasdaqCM (2020-03-27) in USD $1.56
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.37x
United States of America Market PB Ratio Median Figure of 5,156 Publicly-Listed Companies 1.26x
NasdaqCM:DRRX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:DRRX Share Price ÷ Book Value per Share (both in USD)

= 1.56 ÷ 0.12

13.32x

* Primary Listing of DURECT.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DURECT is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess DURECT's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. DURECT has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DRRX Future Performance

 How is DURECT expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-4.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is DURECT expected to grow at an attractive rate?
  • DURECT's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 1.7%.
Growth vs Market Checks
  • DURECT's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • DURECT's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:DRRX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:DRRX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -4.1%
NasdaqCM:DRRX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 34.8%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 28.2%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:DRRX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:DRRX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 159 -38 14 4
2023-12-31 78 -60 -53 4
2022-12-31 45 -54 -63 4
2021-12-31 36 -39 -36 5
2020-12-31 32 -30 -25 5
2020-03-30
NasdaqCM:DRRX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 30 11 -21
2019-09-30 23 1 -24
2019-06-30 20 -19 -24
2019-03-31 19 -19 -24
2018-12-31 19 -20 -25
2018-09-30 34 -21 -10
2018-06-30 35 -17 -1
2018-03-31 36 1 -4
2017-12-31 37 -1 -4
2017-09-30 21 -1 -21
2017-06-30 16 -10 -36
2017-03-31 15 -30 -35

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • DURECT's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • DURECT's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:DRRX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from DURECT Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:DRRX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.01 0.15 -0.10 3.00
2023-12-31 -0.25 -0.11 -0.39 3.00
2022-12-31 -0.29 -0.10 -0.56 3.00
2021-12-31 -0.18 -0.10 -0.34 5.00
2020-12-31 -0.13 -0.10 -0.16 4.00
2020-03-30
NasdaqCM:DRRX Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.12
2019-09-30 -0.14
2019-06-30 -0.15
2019-03-31 -0.15
2018-12-31 -0.16
2018-09-30 -0.06
2018-06-30 -0.01
2018-03-31 -0.03
2017-12-31 -0.03
2017-09-30 -0.15
2017-06-30 -0.25
2017-03-31 -0.25

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if DURECT will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess DURECT's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
DURECT has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DRRX Past Performance

  How has DURECT performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare DURECT's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • DURECT does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare DURECT's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare DURECT's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
DURECT's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from DURECT Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:DRRX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 29.56 -20.58 14.36
2019-09-30 22.51 -23.65 14.11
2019-06-30 19.78 -24.37 13.14
2019-03-31 19.21 -24.16 12.68
2018-12-31 18.56 -25.32 12.42
2018-09-30 34.48 -9.79 12.18
2018-06-30 34.69 -0.96 12.45
2018-03-31 35.59 -3.88 13.32
2017-12-31 36.67 -3.70 13.17
2017-09-30 20.65 -20.74 12.69
2017-06-30 16.15 -35.68 12.60
2017-03-31 14.98 -34.77 11.81
2016-12-31 14.03 -34.51 11.83
2016-09-30 15.68 -31.54 11.84
2016-06-30 16.68 -29.20 11.97
2016-03-31 17.96 -25.66 11.81
2015-12-31 19.12 -22.66 11.57
2015-09-30 18.23 -22.76 11.74
2015-06-30 17.74 -23.36 11.62
2015-03-31 17.88 -23.36 11.74
2014-12-31 19.40 -22.11 12.28
2014-09-30 19.42 -21.27 12.76
2014-06-30 18.13 -20.20 12.81
2014-03-31 17.47 -19.87 13.17
2013-12-31 15.33 -21.45 12.71
2013-09-30 14.30 -21.85 11.98
2013-06-30 15.16 -20.63 11.74
2013-03-31 16.04 -19.81 11.58

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if DURECT has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if DURECT has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if DURECT improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess DURECT's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
DURECT has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DRRX Health

 How is DURECT's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up DURECT's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • DURECT is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • DURECT's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of DURECT's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from DURECT Company Filings, last reported 2 months ago.

NasdaqCM:DRRX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 22.86 20.26 64.67
2019-09-30 22.01 20.95 56.96
2019-06-30 22.89 20.81 37.94
2019-03-31 14.36 20.67 28.63
2018-12-31 20.00 20.53 34.32
2018-09-30 26.09 19.89 41.31
2018-06-30 28.27 19.86 42.40
2018-03-31 30.40 19.83 44.13
2017-12-31 21.49 20.86 36.76
2017-09-30 10.04 19.90 41.67
2017-06-30 -1.84 19.88 33.46
2017-03-31 3.25 19.87 16.68
2016-12-31 8.34 19.85 25.00
2016-09-30 12.94 19.84 27.77
2016-06-30 19.16 19.75 32.56
2016-03-31 10.23 19.72 24.03
2015-12-31 14.88 19.68 29.04
2015-09-30 17.21 19.65 32.19
2015-06-30 22.86 19.86 37.60
2015-03-31 15.48 19.84 29.02
2014-12-31 18.52 19.82 32.70
2014-09-30 23.58 19.81 30.76
2014-06-30 25.07 19.79 32.97
2014-03-31 29.67 0.00 17.81
2013-12-31 30.72 0.00 20.59
2013-09-30 24.17 0.00 17.14
2013-06-30 29.32 0.00 21.01
2013-03-31 33.53 0.00 24.51
  • DURECT's level of debt (88.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (104.6% vs 88.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making DURECT has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making DURECT has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -11.9% per year.
X
Financial health checks
We assess DURECT's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. DURECT has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DRRX Dividends

 What is DURECT's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from DURECT dividends.
If you bought $2,000 of DURECT shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate DURECT's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate DURECT's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:DRRX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 3.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1946 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:DRRX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as DURECT has not reported any payouts.
  • Unable to verify if DURECT's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of DURECT's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as DURECT has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess DURECT's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can DURECT afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. DURECT has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DRRX Management

 What is the CEO of DURECT's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James Brown
COMPENSATION $1,064,696
AGE 62
TENURE AS CEO 21.8 years
CEO Bio

Dr. James E. Brown, D.V.M., Co-founded DURECT Corporation in February 1998 and has been its President and Chief Executive Officer since June 1998. Dr. Brown served as Vice President of Biopharmaceutical and Implant Research and Development of ALZA Corporation from June 1995 to June 1998. Dr. Brown held various positions at Syntex Corporation, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995 and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown has been a Director of DURECT Corporation since June 1998. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from University of California, Davis where he also conducted post-graduate work in Pharmacology and Toxicology.

CEO Compensation
  • James's compensation has been consistent with company performance over the past year, both up more than 20%.
  • James's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the DURECT management team in years:

6
Average Tenure
62
Average Age
  • The average tenure for the DURECT management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

James Brown

TITLE
Co-Founder
COMPENSATION
$1M
AGE
62
TENURE
21.8 yrs

Mike Arenberg

TITLE
Chief Financial Officer
COMPENSATION
$559K
AGE
49
TENURE
1.4 yrs

Judy Joice

TITLE
Senior Vice President of Operations & Corporate Quality Assurance
COMPENSATION
$498K
AGE
62
TENURE
6 yrs

John Gibson

TITLE
VP of Birmingham Operations & Principal Scientist

Steve Helmer

TITLE
VP & Chief Patent Counsel

WeiQi Lin

TITLE
Executive Vice President of Research & Development and Principal Scientist

Jian Li

TITLE
VP of Finance & Corporate Controller
COMPENSATION
$453K
AGE
49
TENURE
18.9 yrs

Su Yum

TITLE
Executive Officer
COMPENSATION
$431K
AGE
80
TENURE
2.2 yrs
Board of Directors Tenure

Average tenure and age of the DURECT board of directors in years:

14.1
Average Tenure
74
Average Age
  • The average tenure for the DURECT board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

David Hoffmann

TITLE
Chairman & Lead Independent Director
COMPENSATION
$146K
AGE
74
TENURE
1.3 yrs

James Brown

TITLE
Co-Founder
COMPENSATION
$1M
AGE
62
TENURE
21.8 yrs

Armand Neukermans

TITLE
Independent Director
COMPENSATION
$148K
AGE
78
TENURE
19 yrs

Simon Benito

TITLE
Independent Director
COMPENSATION
$158K
AGE
74
TENURE
14.9 yrs

Jon Saxe

TITLE
Independent Director
COMPENSATION
$144K
AGE
83
TENURE
16.5 yrs

Terry Blaschke

TITLE
Independent Director
COMPENSATION
$148K
AGE
76
TENURE
13.3 yrs

Judy Robertson

TITLE
Independent Director
AGE
59
TENURE
0.9 yrs

Gail Farfel

TITLE
Independent Director
AGE
55
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
06. Feb 20 Buy Bleichroeder LP Company 04. Feb 20 06. Feb 20 227,498 $1.70 $381,909
24. Jun 19 Buy First Eagle Investment Management, LLC Company 20. Jun 19 20. Jun 19 4,000,000 $0.52 $2,080,000
12. Jun 19 Buy Jon Saxe Individual 10. Jun 19 10. Jun 19 25,000 $0.56 $13,750
28. May 19 Buy Jon Saxe Individual 24. May 19 24. May 19 30,000 $0.63 $18,903
15. May 19 Buy Jon Saxe Individual 13. May 19 13. May 19 9,600 $0.71 $6,773
14. May 19 Buy Jon Saxe Individual 13. May 19 13. May 19 40,400 $0.70 $28,095
X
Management checks
We assess DURECT's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. DURECT has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DRRX News

Simply Wall St News

DRRX Company Info

Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company’s oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

Details
Name: DURECT Corporation
DRRX
Exchange: NasdaqCM
Founded: 1998
$305,477,296
195,818,780
Website: http://www.durect.com
Address: DURECT Corporation
10260 Bubb Road,
Cupertino,
California, 95014,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM DRRX Common Stock Nasdaq Capital Market US USD 28. Sep 2000
DB DC8 Common Stock Deutsche Boerse AG DE EUR 28. Sep 2000
BST DC8 Common Stock Boerse-Stuttgart DE EUR 28. Sep 2000
Number of employees
Current staff
Staff numbers
90
DURECT employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/30 00:27
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/04
Last earnings filing: 2020/03/05
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.